Nektar Therapeutics Company Profile (NASDAQ:NKTR)

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: NKTR
  • CUSIP: 64026810
Key Metrics:
  • Previous Close: $13.70
  • 50 Day Moving Average: $12.89
  • 200 Day Moving Average: $14.64
  • 52-Week Range: $10.67 - $19.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.31
  • P/E Growth: 1.69
  • Market Cap: $2.09B
  • Outstanding Shares: 152,835,000
  • Beta: 1.84
  • Net Margins: -98.87%
  • Return on Equity: -8,769.15%
  • Return on Assets: -35.17%
  • Debt-to-Equity Ratio: -3.61%
  • Current Ratio: 3.70%
  • Quick Ratio: 3.56%
Additional Links:
Companies Related to Nektar Therapeutics:

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.20 (54.74% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
DateFirmActionRatingPrice TargetDetails
1/6/2017BTIG ResearchInitiated CoverageBuy$22.00View Rating Details
12/28/2016AegisReiterated RatingBuy$21.00View Rating Details
12/12/2016Piper Jaffray CompaniesSet Price TargetBuy$25.00View Rating Details
11/7/2016Jefferies Group LLCBoost Price TargetBuy$14.00 -> $15.00View Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00View Rating Details
2/19/2016Roth CapitalReiterated RatingBuyView Rating Details
2/12/2016William BlairReiterated RatingBuyView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
3/18/2015J P Morgan Chase & CoLower Price TargetOverweight$19.00 -> $17.00View Rating Details
(Data available from 2/27/2015 forward)


Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q416($0.26)$40.83 millionN/AView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.24)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.37)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.19)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
Current Year EPS Consensus Estimate: $-1.07 EPS
Next Year EPS Consensus Estimate: $-0.84 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.36)($0.14)($0.23)
Q2 20162($0.35)($0.31)($0.33)
Q3 20163($0.34)($0.27)($0.30)
Q4 20163($0.30)($0.17)($0.23)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.21)($0.21)($0.21)
Q4 20172($0.20)($0.18)($0.19)
Q1 20181($0.12)($0.12)($0.12)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)


Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 86.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.98View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
News IconEvent Spotlight on Opioid Addiction at 17th Annual Pain Therapeutics Summit Featuring Cara Therapeutics, Nektar and Pharmaleads (NASDAQ:NKTR) - February 27 at 5:52 PM
News IconThe Charts For Nektar Therapeutics (NKTR) Is Speaking Volumes Today - NY Stock News (NASDAQ:NKTR) - February 25 at 8:01 AM logoNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets (NASDAQ:NKTR) - February 22 at 6:57 PM
News IconThe Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 1457 Shares of Stock (NASDAQ:NKTR) - February 22 at 8:49 AM
News IconInsider Trading at Nektar Therapeutics? (NASDAQ:NKTR) - February 21 at 6:04 PM
News IconPrice Target & Session Watch on Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) - February 21 at 6:04 PM
News IconTop Earnings Report to Watch for: Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) - February 21 at 6:04 PM
News IconNektar Therapeutics (NKTR) COO John Nicholson Sells 3237 Shares of Stock (NASDAQ:NKTR) - February 21 at 6:04 PM logo2:28 am Nektar Therapeutics reports Phase 1 dose-escalation study of single-agent NKTR-214 indicating encouraging anti-tumor activity (NASDAQ:NKTR) - February 21 at 6:04 PM
News IconNektar presents positive data from phase 1 study of its immuno-oncology agent, NKTR-214 in patients with RCC at ASCO GU 2017 (NASDAQ:NKTR) - February 20 at 6:10 PM logoClinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma ... - PR Newswire (press release) (NASDAQ:NKTR) - February 20 at 9:51 AM logoClinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium (NASDAQ:NKTR) - February 19 at 9:42 AM
News IconAnalyst's Proposition on Invitation Homes Inc. (INVH), Nektar Therapeutics (NKTR) - The USA Commerce (NASDAQ:NKTR) - February 16 at 6:25 PM
News IconAnalyst's Proposition on The Hain Celestial Group, Inc. (HAIN), Nektar Therapeutics (NKTR) - The USA Commerce (NASDAQ:NKTR) - February 13 at 8:01 PM
News IconForward Earnings Estimate of Nektar Therapeutics(NKTR) - Highland Mirror (NASDAQ:NKTR) - February 10 at 7:45 PM
News IconWhy to Keeping Eye on Nektar Therapeutics (NKTR), Mack-Cali Realty Corporation (CLI)? - StockNewsJournal (NASDAQ:NKTR) - February 10 at 7:45 PM
News IconStock Price of Nektar Therapeutics (NKTR) Increases 4.2% (NASDAQ:NKTR) - February 7 at 9:22 PM
News IconEarnings Analysis: Nektar Therapeutics (NASDAQ:NKTR) - The Oracle Examiner (NASDAQ:NKTR) - February 7 at 4:21 PM
News IconBMS' Opdivo approved by FDA as urothelial carcinoma treatment (NASDAQ:NKTR) - February 4 at 12:39 AM
News IconTechnical Study: Following Indicators for Nektar Therapeutics (NKTR) - Springdale Times (NASDAQ:NKTR) - January 31 at 12:32 AM logoExpecting Significant Appreciation For Nektar In 2017 (NASDAQ:NKTR) - January 30 at 7:30 PM
News IconTechnical Review on Shares of Nektar Therapeutics (NKTR) - Sherwood Daily (NASDAQ:NKTR) - January 29 at 5:01 AM
News IconMTA board votes to keep base fare at $2.75, reduce bonuses (NASDAQ:NKTR) - January 26 at 2:08 AM
News IconSilicon Motion Technology Corporation (NASDAQ:SIMO) forecast Q1 revenue of $121 million (NASDAQ:NKTR) - January 25 at 9:07 PM
News IconEarnings in Full Force, Analysts Take Aim at Nektar Therapeutics (NASDAQ:NKTR) - Wall Street Beacon (NASDAQ:NKTR) - January 24 at 7:50 AM
News IconRa Capital Management LLC Has Lifted Its Nektar Therapeutics (NKTR) Stake by $7.47 Million; Valuation Rose - The Randolph Guide (NASDAQ:NKTR) - January 24 at 12:09 AM logoInvestors Snag NKTR 9.0% Cheaper Than Its Secondary Stock Offering (NASDAQ:NKTR) - January 18 at 7:26 PM
News IconTop Stock With Upside & Growth Potential: Nektar Therapeutics (NASDAQ:NKTR) - Prospect Journal (NASDAQ:NKTR) - January 17 at 11:29 AM
News IconDrilling Down Into Nektar Therapeutics (NKTR) | StockNewsJournal - StockNewsJournal (NASDAQ:NKTR) - January 17 at 11:29 AM
News IconCompany Stock Review for Nektar Therapeutics (NASDAQ:NKTR) - Wall Street Beacon (NASDAQ:NKTR) - January 12 at 5:30 AM logoNektar Therapeutics (NKTR) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:NKTR) - January 11 at 7:26 PM logoNEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Other Events (NASDAQ:NKTR) - January 10 at 7:43 PM logoBTIG Starts Nektar Therapeutics (NKTR) at Buy - (NASDAQ:NKTR) - January 8 at 11:34 PM logoAnalyst Activity – BTIG Research Initiates Coverage On Nektar Therapeutics (NASDAQ:NKTR) With a Buy - Market Exclusive (NASDAQ:NKTR) - January 7 at 5:36 AM
News IconNarrowing in on the Numbers for Nektar Therapeutics (NASDAQ:NKTR) - Wall Street Beacon (NASDAQ:NKTR) - January 7 at 12:35 AM logoAnalyst Activity – BTIG Research Initiates Coverage On Nektar Therapeutics (NASDAQ:NKTR) With a Buy (NASDAQ:NKTR) - January 6 at 7:32 PM logoNektar Therapeutics – Value Analysis (NASDAQ:NKTR) : January 6, 2017 (NASDAQ:NKTR) - January 6 at 7:32 PM logoNektar Therapeutics' President and CEO, Howard W. Robin, To ... - PR Newswire (press release) (NASDAQ:NKTR) - January 6 at 1:45 AM logoNektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : January 5, 2017 (NASDAQ:NKTR) - January 5 at 8:42 PM logoNektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA (NASDAQ:NKTR) - January 5 at 8:42 PM logoAnalyst Activity – Aegis Reiterates Buy on Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) - December 29 at 9:34 AM logoNektar Therapeutics (NKTR) Bullish View Reiterated at Aegis Capital as Adynovate Receives Expanded Indications (NASDAQ:NKTR) - December 28 at 6:41 PM logoNektar Therapeutics (NASDAQ:NKTR) EPS Projection At $-0.26? - Stocks Daily (NASDAQ:NKTR) - December 28 at 10:03 AM logoETFs with exposure to Nektar Therapeutics : December 27, 2016 (NASDAQ:NKTR) - December 27 at 6:43 PM logoNektar Therapeutics : Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings (NASDAQ:NKTR) - December 27 at 10:04 AM
News IconMarket Corner: Eye on Technicals for Nektar Therapeutics (NKTR) - StockTalk Daily (NASDAQ:NKTR) - December 20 at 12:48 PM
News IconCompany Stock Focus on Nektar Therapeutics (NASDAQ:NKTR) - Business Daily Leader (NASDAQ:NKTR) - December 20 at 12:48 PM
News IconEquity Rundown: RSI and CCI Check on Nektar Therapeutics (NKTR) - StockTalk Daily (NASDAQ:NKTR) - December 17 at 7:14 PM logoETFs with exposure to Nektar Therapeutics : December 16, 2016 (NASDAQ:NKTR) - December 16 at 7:34 PM
News IconNektar Therapeutics (NKTR) Position Boosted by Rice Hall James & Associates LLC (NASDAQ:NKTR) - December 15 at 7:45 PM


What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2017?

5 analysts have issued twelve-month target prices for Nektar Therapeutics' shares. Their forecasts range from $15.00 to $25.00. On average, they expect Nektar Therapeutics' stock price to reach $21.20 in the next year.

When will Nektar Therapeutics announce their earnings?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Nektar Therapeutics stock?

Nektar Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (2.66%), Janus Capital Management LLC (1.17%), FMR LLC (0.89%), Federated Investors Inc. PA (0.67%), Two Sigma Investments LP (0.66%) and Marshall Wace LLP (0.54%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Stephen K Doberstein and Susan Wang.

Who sold Nektar Therapeutics stock? Who is selling Nektar Therapeutics stock?

Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Oxford Asset Management, Dimensional Fund Advisors LP, Allianz Asset Management AG, Janus Capital Management LLC, Guggenheim Capital LLC, Pacad Investment Ltd. and AQR Capital Management LLC. Company insiders that have sold Nektar Therapeutics stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Robert Chess and Stephen K Doberstein.

Who bought Nektar Therapeutics stock? Who is buying Nektar Therapeutics stock?

Nektar Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Two Sigma Investments LP, Marshall Wace LLP, J. Goldman & Co LP, Advisory Research Inc., Highland Capital Management LP, Numeric Investors LLC and Russell Investments Group Ltd..

How do I buy Nektar Therapeutics stock?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nektar Therapeutics stock cost?

One share of Nektar Therapeutics stock can currently be purchased for approximately $13.70.

Nektar Therapeutics (NASDAQ:NKTR) Chart for Monday, February, 27, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Earnings History Chart

Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Dividend History Chart

Dividend Payments by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Last Updated on 2/27/2017 by Staff